Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 17/20 | 0.67 |
| ▸ | OXTR | P30559 | 2/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5420934 | 0.90 | AVPR1B (0.67) | AVPR1BOXTRAVPR1AMEN1KMT2A | |
| SCHEMBL5422293 | 0.87 | AVPR1B (0.64) | AVPR1BOXTRAVPR1AAVPR2MEN1 | |
| SCHEMBL16857954 | 0.85 | AVPR1B (0.57) | AVPR1BMEN1KMT2AALDH1A1 | |
| SCHEMBL1465221 | 0.84 | AVPR1B (0.69) | AVPR1BOXTRAVPR1AAVPR2 | |
| SCHEMBL2891438 | 0.82 | AVPR1B (0.88) | AVPR1B | |
| SCHEMBL1465248 | 0.80 | AVPR1B (0.65) | AVPR1BOXTRAVPR1AAVPR2ALDH1A1 | |
| SCHEMBL1466131 | 0.80 | AVPR1B (0.65) | AVPR1BOXTRAVPR1AAVPR2MEN1 | |
| SCHEMBL5420928 | 0.79 | AVPR1B (0.65) | AVPR1BOXTRAVPR1AAVPR2MEN1 | |
| SCHEMBL1465491 | 0.79 | AVPR1B (0.59) | AVPR1BOXTRAVPR1AAVPR2ALDH1A1 | |
| SCHEMBL1590457 | 0.78 | AVPR1B (0.61) | AVPR1BOXTRAVPR1AAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667993-B1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2015-07-01 | — | — | EP | claimed |
| US-20170050959-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2017-02-23 | — | — | US | disclosed |
| US-9487505-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-11-08 | — | — | US | disclosed |
| EP-1667993-B1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-20140187543-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8580842-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG (DE) | 2013-11-12 | — | — | US | disclosed |
| EP-2546251-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546252-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546250-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-8350055-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG (DE) | 2013-01-08 | — | — | US | disclosed |
| US-20070185126-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing Them | AbbVie Deutschland GmbH & Co. KG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-20070021607-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG. | 2007-01-25 | — | — | US | disclosed |
| EP-1667993-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | Abbott GmbH & Co. KG (DE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030755-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBOTT GMBH & CO. KG (DE) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070718-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070718-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | OXTR, AVPR2, AVPR1A | AVPR1B 4/4885OXTR 1/4885AVPR1A 3/4885 |
| US-20070021607-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | OXTR, AVPR2, AVPR1A | AVPR1B 4/4885OXTR 1/4885AVPR1A 3/4885 |
| US-20140187543-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | OXTR, AVPR2, AVPR1A | AVPR1B 4/4885OXTR 1/4885AVPR1A 3/4885 |
| US-20070185126-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing Them | OXTR, AVPR2, AVPR1A | AVPR1B 4/4885OXTR 1/4885AVPR1A 3/4885 |
| US-20170050959-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | OXTR, AVPR2, AVPR1A | AVPR1B 4/4885OXTR 1/4885AVPR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.